Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner,Cell Host & Microbe

当前位置： X-MOL 学术 › Cell Host Microbe › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner
Cell Host & Microbe ( IF 20.6 ) Pub Date : 2021-10-13 , DOI: 10.1016/j.chom.2021.10.003
Roanne Keeton ₁ , Simone I Richardson ₂ , Thandeka Moyo-Gwete ₂ , Tandile Hermanus ₂ , Marius B Tincho ₁ , Ntombi Benede ₁ , Nelia P Manamela ₂ , Richard Baguma ₃ , Zanele Makhado ₂ , Amkele Ngomti ₁ , Thopisang Motlou ₂ , Mathilda Mennen ₄ , Lionel Chinhoyi ₄ , Sango Skelem ₄ , Hazel Maboreke ₅ , Deelan Doolabh ₁ , Arash Iranzadeh ₁ , Ashley D Otter ₆ , Tim Brooks ₆ , Mahdad Noursadeghi ₇ , James C Moon ₈ , Alba Grifoni ₉ , Daniela Weiskopf ₉ , Alessandro Sette ₁₀ , Jonathan Blackburn ₅ , Nei-Yuan Hsiao ₁₁ , Carolyn Williamson ₁₂ , Catherine Riou ₁₂ , Ameena Goga ₁₃ , Nigel Garrett ₁₄ , Linda-Gail Bekker ₁₅ , Glenda Gray ₁₃ , Ntobeko A B Ntusi ₁₆ , Penny L Moore ₂ , Wendy A Burgers ₁₂

Affiliation

Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Department of Medicine, University of Cape Town and Groote Schuur Hospital, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Division of Chemical and Systems Biology, Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town, South Africa.
National Infection Service, Public Health England, Porton Down, UK.
Division of Infection and Immunity, University College London, London, UK.
Institute of Cardiovascular Sciences, University College London, London, UK; Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA, USA.
Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa; NHLS Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa; Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa.
South African Medical Research Council, Cape Town, South Africa.
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa; Discipline of Public Health Medicine, University of KwaZulu-Natal, Durban, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Desmond Tutu HIV Centre, Cape Town, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Department of Medicine, University of Cape Town and Groote Schuur Hospital, South Africa; Hatter Institute for Cardiovascular Research in Africa, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

The Johnson and Johnson Ad26.COV2.S single-dose vaccine represents an attractive option for coronavirus disease 2019 (COVID-19) vaccination in countries with limited resources. We examined the effect of prior infection with different SARS-CoV-2 variants on Ad26.COV2.S immunogenicity. We compared participants who were SARS-CoV-2 naive with those either infected with the ancestral D614G virus or infected in the second wave when Beta predominated. Prior infection significantly boosts spike-binding antibodies, antibody-dependent cellular cytotoxicity, and neutralizing antibodies against D614G, Beta, and Delta; however, neutralization cross-reactivity varied by wave. Robust CD4 and CD8 T cell responses are induced after vaccination, regardless of prior infection. T cell recognition of variants is largely preserved, apart from some reduction in CD8 recognition of Delta. Thus, Ad26.COV2.S vaccination after infection could result in enhanced protection against COVID-19. The impact of the infecting variant on neutralization breadth after vaccination has implications for the design of second-generation vaccines based on variants of concern.

中文翻译：

既往感染 SARS-CoV-2 会以变异依赖性方式增强和扩大 Ad26.COV2.S 的免疫原性

强生 Ad26.COV2.S 单剂量疫苗是资源有限的国家 2019 年冠状病毒病 (COVID-19) 疫苗接种的一个有吸引力的选择。我们检查了先前感染不同 SARS-CoV-2 变体对 Ad26.COV2.S 免疫原性的影响。我们将未感染 SARS-CoV-2 的参与者与感染祖先 D614G 病毒或在第二波 Beta 病毒占主导地位时感染的参与者进行了比较。既往感染可显着增强刺突结合抗体、抗体依赖性细胞毒性以及针对 D614G、Beta 和 Delta 的中和抗体；然而，中和交叉反应因波而异。无论先前是否感染，疫苗接种后都会诱导强大的 CD4 和 CD8 T 细胞反应。T 细胞对变异的识别在很大程度上得以保留，除了 Delta 的 CD8 识别度有所降低之外。因此，感染后接种 Ad26.COV2.S 疫苗可能会增强对 COVID-19 的保护。感染变体对疫苗接种后中和广度的影响对于基于所关注变体的第二代疫苗的设计具有影响。

更新日期：2021-11-10

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11